If epigastric pain occurs after taking Lenvatinib, the drug should be discontinued and the symptoms should be relieved before regularizing the use of the drug as prescribed by the doctor.
If epigastric pain occurs after taking lenvatinib, if the degree is more serious, the patient can first stop taking the drug, and then resume taking the drug as prescribed by the doctor after the symptoms disappear.
In addition, severe diarrhea may occur after taking Lenvatinib, this situation requires standard anti-diarrhea treatment. Note that if grade 3 diarrhea occurs after use of the drug should be suspended taking lenvatinib, grade 4 diarrhea should be terminated treatment.
Lenvatinib is a multi-targeted receptor tyrosine kinase inhibitor that produces a comprehensive inhibitory effect on tumors through multiple targets. It is currently approved for the treatment of patients with hepatocellular carcinoma, for the treatment of aggressive, locally advanced or metastatic differentiated thyroid cancer, and in combination with everolimus for the treatment of advanced renal cell carcinoma.
Lenvatinib must be taken as prescribed by the doctor during medication, and should not be taken by pregnant women, nursing mothers, or those with bleeding conditions.